CAP-话题@MedSci

#CAP#

167篇内容 | 3518人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1898005, encodeId=93941898005e4, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=Hepatology：Glecaprevir/Pibrentasvir治疗先前直接抗病毒治疗失败的HCV基因1型或4型患者, objectType=article, longId=121391, objectId=5d1812139172, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d1812139172, replyNumber=0, likeNumber=73, createdTime=2018-07-05, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d1812139172, moduleTitle=Hepatology：Glecaprevir/Pibrentasvir治疗先前直接抗病毒治疗失败的HCV基因1型或4型患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d1812139172)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1897993, encodeId=faa0189e9931e, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=Cardiovasc Ther：CAPS研究：心血管事件二级预防更佳药物治疗和药物依从性, objectType=article, longId=95896, objectId=035c958964a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=035c958964a, replyNumber=0, likeNumber=82, createdTime=2017-11-27, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=035c958964a, moduleTitle=Cardiovasc Ther：CAPS研究：心血管事件二级预防更佳药物治疗和药物依从性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=035c958964a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1897994, encodeId=e4e2189e99466, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=PLos One：联合使用CAP与超声诊断血液透析患者中非酒精性脂肪肝的发病情况, objectType=article, longId=96802, objectId=4cb896802ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cb896802ee, replyNumber=0, likeNumber=59, createdTime=2017-10-17, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cb896802ee, moduleTitle=PLos One：联合使用CAP与超声诊断血液透析患者中非酒精性脂肪肝的发病情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cb896802ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1897998, encodeId=0f3d189e998f0, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=J Microencap：槲皮素可用于食物, objectType=article, longId=111088, objectId=80b011108875, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80b011108875, replyNumber=0, likeNumber=65, createdTime=2018-05-24, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80b011108875, moduleTitle=J Microencap：槲皮素可用于食物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80b011108875)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1897999, encodeId=fb43189e9996d, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=【ESC 2017】CAPTAF研究结果公布, objectType=article, longId=111269, objectId=a951111269ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a951111269ba, replyNumber=0, likeNumber=62, createdTime=2017-10-16, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a951111269ba, moduleTitle=【ESC 2017】CAPTAF研究结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a951111269ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1897996, encodeId=4fd7189e9966c, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=Hepatology：glecaprevir和pibrentasvir在HCV基因1型感染及有DAA用药史的患者中治疗12周的效果评估, objectType=article, longId=100454, objectId=b2501004549d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2501004549d, replyNumber=0, likeNumber=80, createdTime=2017-11-24, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2501004549d, moduleTitle=Hepatology：glecaprevir和pibrentasvir在HCV基因1型感染及有DAA用药史的患者中治疗12周的效果评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2501004549d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898002, encodeId=06cb1898002bf, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=凯瑞康宁获Elements Capital和WI Harper领衔的1750万美元B轮融资, objectType=article, longId=113784, objectId=561d113e841d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=561d113e841d, replyNumber=0, likeNumber=65, createdTime=2018-03-11, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=561d113e841d, moduleTitle=凯瑞康宁获Elements Capital和WI Harper领衔的1750万美元B轮融资, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=561d113e841d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1897995, encodeId=b43a189e9953d, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=CCLM：ImmunoCAP®ISAC 112的性能评估, objectType=article, longId=98809, objectId=be3298809fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be3298809fb, replyNumber=0, likeNumber=79, createdTime=2018-02-23, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be3298809fb, moduleTitle=CCLM：ImmunoCAP®ISAC 112的性能评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be3298809fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1897989, encodeId=4bc7189e98936, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=2012AACAP实践参数——儿童心理治疗发布, objectType=article, longId=76534, objectId=4737e653479, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4737e653479, replyNumber=0, likeNumber=22, createdTime=2017-01-29, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4737e653479, moduleTitle=2012AACAP实践参数——儿童心理治疗发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4737e653479)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1897987, encodeId=fe46189e9873d, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=2016梅奥CAP-TMA疾病小组共识——血栓性微血管病的护理路径发布, objectType=article, longId=74916, objectId=0579e49165c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0579e49165c, replyNumber=0, likeNumber=33, createdTime=2016-11-03, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0579e49165c, moduleTitle=2016梅奥CAP-TMA疾病小组共识——血栓性微血管病的护理路径发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0579e49165c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1897990, encodeId=cdbc189e99099, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=癌症序列变异解释和报告的标准和指南（ASCO和CAP联合推荐）, objectType=article, longId=84835, objectId=463c84835df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=463c84835df, replyNumber=0, likeNumber=63, createdTime=2017-03-20, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=463c84835df, moduleTitle=癌症序列变异解释和报告的标准和指南（ASCO和CAP联合推荐）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=463c84835df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1897991, encodeId=6be4189e99169, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=FDA批准Clovis PARP抑制剂rucaparib, objectType=article, longId=84882, objectId=d7298488274, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7298488274, replyNumber=0, likeNumber=60, createdTime=2016-12-31, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7298488274, moduleTitle=FDA批准Clovis PARP抑制剂rucaparib, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d7298488274)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1897992, encodeId=8be6189e9926c, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=Medscape：2016年度更佳医生Top11, objectType=article, longId=85163, objectId=cbe185163a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbe185163a3, replyNumber=0, likeNumber=58, createdTime=2017-04-11, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbe185163a3, moduleTitle=Medscape：2016年度更佳医生Top11, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbe185163a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1897985, encodeId=4f3b189e985c4, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=EHJ：中国择期PCI患者他汀强化未进一步获益(ISCAP研究), objectType=article, longId=61113, objectId=7a386111388, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a386111388, replyNumber=0, likeNumber=69, createdTime=2016-02-29, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a386111388, moduleTitle=EHJ：中国择期PCI患者他汀强化未进一步获益(ISCAP研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a386111388)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1897988, encodeId=bf3d189e98805, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=Capita建立战略合作关系，力促中国医疗卫生发展, objectType=article, longId=75808, objectId=d24ce58083e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d24ce58083e, replyNumber=0, likeNumber=70, createdTime=2017-08-02, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d24ce58083e, moduleTitle=Capita建立战略合作关系，力促中国医疗卫生发展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d24ce58083e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1897984, encodeId=1031189e98440, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=JAACAP：看好你的孩子，十分之一的学龄前儿童有自杀念头和行为, objectType=article, longId=59651, objectId=1f6c5965133, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f6c5965133, replyNumber=0, likeNumber=75, createdTime=2016-09-29, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f6c5965133, moduleTitle=JAACAP：看好你的孩子，十分之一的学龄前儿童有自杀念头和行为, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f6c5965133)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1897982, encodeId=ba18189e98210, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=AJRCCM：十年间社区获得性肺炎（CAP）的死亡率研究, objectType=article, longId=52929, objectId=12475292968, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12475292968, replyNumber=0, likeNumber=62, createdTime=2016-05-15, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12475292968, moduleTitle=AJRCCM：十年间社区获得性肺炎（CAP）的死亡率研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12475292968)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1897986, encodeId=1e61189e986ed, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=NEJM：Caplacizumab可缓解获得性血栓性血小板减少性紫癜，但增加出血危险, objectType=article, longId=63155, objectId=fb1d63155ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb1d63155ea, replyNumber=0, likeNumber=73, createdTime=2016-10-26, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb1d63155ea, moduleTitle=NEJM：Caplacizumab可缓解获得性血栓性血小板减少性紫癜，但增加出血危险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb1d63155ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1897981, encodeId=564d189e981e7, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=JCAP：阿托西汀用于儿童注意缺陷/多动症状的功效, objectType=article, longId=49738, objectId=f4a549e38af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4a549e38af, replyNumber=0, likeNumber=54, createdTime=2015-11-02, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4a549e38af, moduleTitle=JCAP：阿托西汀用于儿童注意缺陷/多动症状的功效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4a549e38af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1897972, encodeId=4a22189e97205, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=Mescape：电子香烟需要新的研究并加强管制, objectType=article, longId=46534, objectId=608846534b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=608846534b9, replyNumber=0, likeNumber=53, createdTime=2015-12-19, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=608846534b9, moduleTitle=Mescape：电子香烟需要新的研究并加强管制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=608846534b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CAP

2020-05-29

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

Hepatology：Glecaprevir/Pibrentasvir治疗先前直接抗病毒治疗失败的HCV基因1型或4型患者

2018-07-05

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

Cardiovasc Ther：CAPS研究：心血管事件二级预防更佳药物治疗和药物依从性

2017-11-27

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

PLos One：联合使用CAP与超声诊断血液透析患者中非酒精性脂肪肝的发病情况

2017-10-17

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

J Microencap：槲皮素可用于食物

2018-05-24

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

【ESC 2017】CAPTAF研究结果公布

2017-10-16

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

Hepatology：glecaprevir和pibrentasvir在HCV基因1型感染及有DAA用药史的患者中治疗12周的效果评估

2017-11-24

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

凯瑞康宁获Elements Capital和WI Harper领衔的1750万美元B轮融资

2018-03-11

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

CCLM：ImmunoCAP®ISAC 112的性能评估

2018-02-23

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

2012AACAP实践参数——儿童心理治疗发布

2017-01-29

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

2016梅奥CAP-TMA疾病小组共识——血栓性微血管病的护理路径发布

2016-11-03

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

癌症序列变异解释和报告的标准和指南（ASCO和CAP联合推荐）

2017-03-20

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

FDA批准Clovis PARP抑制剂rucaparib

2016-12-31

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

Medscape：2016年度更佳医生Top11

2017-04-11

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

EHJ：中国择期PCI患者他汀强化未进一步获益(ISCAP研究)

2016-02-29

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

Capita建立战略合作关系，力促中国医疗卫生发展

2017-08-02

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

JAACAP：看好你的孩子，十分之一的学龄前儿童有自杀念头和行为

2016-09-29

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

AJRCCM：十年间社区获得性肺炎（CAP）的死亡率研究

2016-05-15

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

NEJM：Caplacizumab可缓解获得性血栓性血小板减少性紫癜，但增加出血危险

2016-10-26

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

JCAP：阿托西汀用于儿童注意缺陷/多动症状的功效

2015-11-02

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

Mescape：电子香烟需要新的研究并加强管制

2015-12-19

科室
- - 订阅+
  - 更多科室
工具
服务